FR21C1031I2 - Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives - Google Patents

Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives

Info

Publication number: FR21C1031I2
Authority: FR; France
Prior art keywords: treatment; inhibitors; quinazolin; phenyl; similar compounds
Prior art date: 2005-11-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1031C

Other languages

English (en)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Array Biopharma Inc

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-15

Filing date

2021-07-20

Publication date

2022-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38022019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-07-20 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2021-08-27 Publication of FR21C1031I1 publication Critical patent/FR21C1031I1/fr

2022-07-15 Application granted granted Critical

2022-07-15 Publication of FR21C1031I2 publication Critical patent/FR21C1031I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Oncology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Mycology (AREA)
Microbiology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)

FR21C1031C 2005-11-15 2021-07-20 Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives Active FR21C1031I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73628905P	2005-11-15	2005-11-15
US81701906P	2006-06-28	2006-06-28
PCT/US2006/044431 WO2007059257A2 (fr)	2005-11-15	2006-11-15	Inhibiteurs erbb

Publications (2)

Publication Number	Publication Date
FR21C1031I1 FR21C1031I1 (fr)	2021-08-27
FR21C1031I2 true FR21C1031I2 (fr)	2022-07-15

Family

ID=38022019

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1031C Active FR21C1031I2 (fr)	2005-11-15	2021-07-20	Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives

Country Status (28)

Country	Link
US (6)	US8648087B2 (fr)
EP (2)	EP2090575B1 (fr)
JP (2)	JP5134548B2 (fr)
KR (1)	KR101086967B1 (fr)
CN (2)	CN102887891B (fr)
AT (2)	ATE507224T1 (fr)
AU (2)	AU2006315383B2 (fr)
BR (2)	BRPI0618668B1 (fr)
CA (2)	CA2755268C (fr)
CY (3)	CY1110583T1 (fr)
DE (2)	DE602006009968D1 (fr)
DK (2)	DK2090575T3 (fr)
ES (2)	ES2335535T3 (fr)
FI (1)	FIC20210022I1 (fr)
FR (1)	FR21C1031I2 (fr)
HU (1)	HUS2100028I1 (fr)
IL (2)	IL239149A (fr)
LT (1)	LTC1971601I2 (fr)
LU (1)	LUC00217I2 (fr)
NL (1)	NL301113I2 (fr)
NO (1)	NO342413B1 (fr)
PL (2)	PL2090575T3 (fr)
PT (2)	PT2090575E (fr)
RU (2)	RU2592703C9 (fr)
SG (1)	SG152230A1 (fr)
SI (2)	SI1971601T1 (fr)
WO (1)	WO2007059257A2 (fr)
ZA (1)	ZA200804498B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
NZ545459A (en)	2003-08-14	2009-12-24	Array Biopharma Inc	Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
DE602006009968D1 (de)	2005-11-15	2009-12-03	Array Biopharma Inc	N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
AU2007296744A1 (en) *	2006-09-11	2008-03-20	Curis, Inc.	Multi-functional small molecules as anti-proliferative agents
EP2061773A4 (fr) *	2006-09-11	2011-01-19	Curis Inc	Inhibiteurs d'egfr à base de quinazoline contenant un fragment de liaison au zinc
US7547781B2 (en)	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CL2008001626A1 (es) *	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
JP5433579B2 (ja)	2007-09-14	2014-03-05	ジャンセンファーマシューティカルズ，インコーポレイテッド．	１，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
ATE516272T1 (de)	2007-09-14	2011-07-15	Ortho Mcneil Janssen Pharm	1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
TWI475995B (zh)	2007-09-14	2015-03-11	Janssen Pharmaceuticals Inc	１’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物
AU2008323287B2 (en)	2007-11-14	2011-07-14	Addex Pharma S.A.	Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (fr)	2008-09-02	2013-11-06	Janssen Pharmaceuticals, Inc.	Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate
US8293897B2 (en)	2008-10-14	2012-10-23	Ning Xi	Compounds comprising a spiro-ring and methods of use
RU2517181C2 (ru)	2008-10-16	2014-05-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en)	2008-11-28	2014-04-08	Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011006220A (es)	2008-12-11	2011-06-28	Respivert Ltd	Inhibidores de la proteina cinasa activada por el mitogeno p38.
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh)	2009-05-12	2015-05-13	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2440001T3 (es)	2009-05-12	2014-01-27	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
US8586581B2 (en)	2009-12-17	2013-11-19	Hoffmann-La Roche Inc	Ethynyl compounds useful for treatment of CNS disorders
US8343977B2 (en)	2009-12-30	2013-01-01	Arqule, Inc.	Substituted triazolo-pyrimidine compounds
CN102382106A (zh) *	2010-08-30	2012-03-21	黄振华	苯胺取代的喹唑啉衍生物
US8993591B2 (en)	2010-11-08	2015-03-31	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (fr)	2010-11-08	2012-05-18	Janssen Pharmaceuticals, Inc.	Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
CN103298810B (zh)	2010-11-08	2016-03-16	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US9173887B2 (en)	2010-12-22	2015-11-03	Abbvie Inc.	Hepatitis C inhibitors and uses thereof
JP2014156400A (ja) *	2011-05-24	2014-08-28	Astellas Pharma Inc	腫瘍の画像診断用標識誘導体
BR112014009084B1 (pt) *	2011-10-14	2021-09-21	Array Biopharma Inc	Polimorfos cristalinos de arry-380
WO2013056108A2 (fr) *	2011-10-14	2013-04-18	Array Biopharma Inc.	Dispersion solide
ES2855142T3 (es) *	2012-03-23	2021-09-23	Array Biopharma Inc	Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+
SI2964638T1 (sl) *	2013-03-06	2017-11-30	Astrazeneca Ab	Kinazolinski inhibitorji aktiviranja mutantnih oblik receptorja epidermalnega rastnega faktorja
CA2903288C (fr) *	2013-03-15	2021-09-21	Deciphera Pharmaceuticals, Llc	N-acyl-n'-(pyridin-2-yl)urees et analogues montrant des activites anticancereuses et antiproliferatives
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2015008844A1 (fr)	2013-07-18	2015-01-22	大鵬薬品工業株式会社	Agent thérapeutique pour un cancer résistant à un inhibiteur de fgfr
TR201907147T4 (tr) *	2013-07-18	2019-06-21	Taiho Pharmaceutical Co Ltd	Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3424535A1 (fr)	2014-01-21	2019-01-09	Janssen Pharmaceutica NV	Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de récepteurs glutamatergiques métabotropes de sous-type 2 et leur utilisation
PH12019500127B1 (en)	2014-01-21	2022-05-04	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
AU2015362670B2 (en)	2014-12-15	2019-01-24	The Regents Of The University Of Michigan	Small molecule inhibitors of EGFR and PI3K
PL3279202T3 (pl)	2015-03-31	2020-12-28	Taiho Pharmaceutical Co., Ltd.	Kryształ 3,5-dipodstawionego związku benzenoalkinylowego
JP6791979B2 (ja) *	2016-03-01	2020-11-25	シャンハイファーマシューティカルズホールディングカンパニー，リミティド	含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
KR102793563B1 (ko)	2016-03-04	2025-04-11	다이호야쿠힌고교 가부시키가이샤	악성 종양 치료용 제제 및 조성물
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
CN106117182B (zh) *	2016-06-20	2019-08-30	中国药科大学	喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
WO2018040885A1 (fr) *	2016-09-01	2018-03-08	南京药捷安康生物科技有限公司	Inhibiteurs du récepteur du facteur de croissance des fibroblastes et leur utilisation
EP3516071B1 (fr)	2016-09-22	2021-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédé et compositions pharmaceutiques de traitement du cancer du poumon
WO2018121758A1 (fr) *	2016-12-30	2018-07-05	南京明德新药研发股份有限公司	Composé quinazoline pour l'inhibition de l'egfr
MA49059A (fr)	2017-04-28	2021-03-24	Seagen Inc	Traitement des cancers positifs à her2
JP7333313B2 (ja) *	2017-09-01	2023-08-24	シャンハイファーマシューティカルズホールディングカンパニー，リミティド	窒素含有複素環化合物、製造方法、中間体、組成物および使用
MY203305A (en)	2018-03-19	2024-06-23	Taiho Pharmaceutical Co Ltd	Pharmaceutical composition including sodium alkyl sulfate
US20220411422A1 (en) *	2018-05-08	2022-12-29	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Erbb receptor inhibitors
WO2019214651A1 (fr) *	2018-05-08	2019-11-14	南京明德新药研发有限公司	Dérivés de pyrrolo[2,1-f][1,2,4]triazine servant d'inhibiteurs sélectifs de her2 et leur application
TWI811358B (zh) *	2018-05-08	2023-08-11	大陸商迪哲（江蘇）醫藥股份有限公司	ＥｒｂＢ受體抑制劑
RS65413B1 (sr) *	2018-09-18	2024-05-31	Hoffmann La Roche	Derivati hinazolina kao antitumorski agensi
CN109942576B (zh) *	2019-03-07	2020-09-11	上海工程技术大学	Irbinitinib及中间体的制备方法
CN111825604A (zh) *	2019-04-16	2020-10-27	宁波药腾医药科技有限公司	一种图卡替尼及其中间产物的合成方法
WO2021088987A1 (fr) *	2019-11-08	2021-05-14	南京明德新药研发有限公司	Forme saline servant d'inhibiteur sélectif de her2, et formes cristallines et utilisation de celle-ci
EP4100412A1 (fr) *	2020-02-03	2022-12-14	Boehringer Ingelheim International GmbH	[1,3]diazino[5,4-d]pyrimidines utilisées en tant qu'inhibiteurs de her2
JP7626773B2 (ja) *	2020-02-03	2025-02-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
AU2020435503B2 (en) *	2020-03-13	2025-02-20	F. Hoffmann-La Roche Ag	ErbB receptor inhibitors as anti-tumor agents
US11608343B2 (en) *	2020-04-24	2023-03-21	Boehringer Ingelheim International Gmbh	Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) *	2020-06-30	2022-04-16	美商艾瑞生藥股份有限公司	Ｈｅｒ２突變抑制劑
MX2023007550A (es)	2020-12-22	2023-11-14	Mekanistic Therapeutics Llc	Compuestos de aminobencil heteroarilo sustituidos como inhibidores de receptor de factor de crecimiento epidermico (egfr) y/o fosfoinositol 3-cinasa (pi3k).
WO2022140769A1 (fr) *	2020-12-22	2022-06-30	Enliven Therapeutics, Inc.	Dérivés de pyrimidine à fusion hétéroaryle lactame servant d'inhibiteurs d'erbb2
WO2022198231A1 (fr)	2021-03-18	2022-09-22	Seagen Inc.	Libération sélective de médicament à partir de conjugués internalisés de composés biologiquement actifs
BR112023021111A2 (pt)	2021-04-13	2023-12-19	Nuvalent Inc	Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
PE20250118A1 (es)	2021-06-26	2025-01-16	Array Biopharma Inc	Inhibidores de mutacion de her2
KR102598580B1 (ko) *	2021-07-16	2023-11-06	한양대학교 에리카산학협력단	니트로알켄 화합물의 신규 제조방법
WO2023081637A1 (fr)	2021-11-02	2023-05-11	Enliven Therapeutics, Inc.	Dérivés de quinazoline tétracycliques fusionnés utilisés en tant qu'inhibiteurs d'erbb2
KR102884401B1 (ko) *	2022-02-25	2025-11-11	중앙대학교 산학협력단	헤테로아릴 유도체를 유효성분으로 함유하는 her2 억제용 조성물
CN118715216A (zh) *	2022-03-28	2024-09-27	江苏恒瑞医药股份有限公司	含氮杂环类化合物、其制备方法及其在医药上的应用
JP2025510926A (ja) *	2022-04-05	2025-04-15	ボロノイインコーポレイテッド	ヘテロアリール誘導体およびその使用
CN117384162A (zh) *	2022-05-17	2024-01-12	浙江文达医药科技有限公司	选择性her2抑制剂
WO2024027695A1 (fr) *	2022-08-04	2024-02-08	微境生物医药科技(上海)有限公司	Composés utiles comme inhibiteurs de her2
CN115650975B (zh) *	2022-08-23	2024-07-02	四川大学华西医院	一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用
WO2025034912A2 (fr)	2023-08-07	2025-02-13	Cogent Biosciences, Inc.	Composés pour inhiber fgfr
WO2025067396A1 (fr) *	2023-09-27	2025-04-03	江苏恒瑞医药股份有限公司	Sel pharmaceutiquement acceptable et forme cristalline d'un dérivé de quinazoline, et leur utilisation
WO2025067398A1 (fr) *	2023-09-27	2025-04-03	江苏恒瑞医药股份有限公司	Forme cristalline d'un dérivé de la quinazoline et son procédé de préparation
CN118084901A (zh) *	2023-12-15	2024-05-28	江苏希迪制药有限公司	妥卡替尼的合成方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
BE795970A (fr) *	1972-02-29	1973-08-27	Pfizer	Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) *	1972-02-29	1977-06-14	Pfizer Inc.	(2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
DE2653005A1 (de) *	1975-12-03	1977-06-08	Sandoz Ag	Neue organische verbindungen, ihre verwendung und herstellung
US6743782B1 (en)	1987-10-28	2004-06-01	Wellstat Therapeutics Corporation	Acyl deoxyribonucleoside derivatives and uses thereof
US5204348A (en) *	1988-10-06	1993-04-20	Mitsui Toatsu Chemicals Inc.	Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
CA1340821C (fr) *	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Composes heterocycliques, ainsi que des adjuvants de produits anti-cancereux les comprenant
US5517680A (en)	1992-01-22	1996-05-14	Ericsson Inc.	Self correction of PST simulcast system timing
US5502187A (en) *	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
JP3398152B2 (ja) *	1993-10-12	2003-04-21	ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー	１ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (fr) *	1994-11-12	1997-12-01	Zeneca Ltd
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
AR004010A1 (es) *	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
KR19990082463A (ko) *	1996-02-13	1999-11-25	돈 리사 로얄	혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
EA001595B1 (ru) *	1996-04-12	2001-06-25	Варнер-Ламберт Компани	Необратимые ингибиторы тирозинкиназ
AR007857A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6225318B1 (en) *	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
ZA986732B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
DE19735682A1 (de)	1997-08-19	1999-02-25	Basf Ag	Verfahren zur Herstellung von 3-Isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-on-2,2-dioxid
BR9814018A (pt) *	1997-11-11	2000-09-26	Pfizer Prod Inc	Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
JP2002505288A (ja) *	1998-03-02	2002-02-19	コセンシス，インコーポレイテッド	置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) *	1998-05-18	2000-01-25	U.S. Bioscience, Inc.	Thermally stable trimetrexates and processes for producing the same
PT1131304E (pt) *	1998-11-19	2003-04-30	Warner Lambert Co	N-¬4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il\|-acrilamida um inibidor irreversivel de tirosino quinases
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
AU2203700A (en) *	1999-01-13	2000-08-01	Warner-Lambert Company	Benzoheterocycles and their use as mek inhibitors
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
GB9910577D0 (en) *	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
EE200200149A (et) *	1999-09-21	2003-04-15	Astrazeneca Ab	Kinasoliinühendid ja neid sisaldavad ravimkoostised
WO2001094353A1 (fr) *	2000-06-06	2001-12-13	Pfizer Products Inc.	Derives de thiophene utilises comme agents anticancereux
EP1289952A1 (fr)	2000-05-31	2003-03-12	AstraZeneca AB	Derives d'indole possedant une activite endommageant les vaisseaux sanguins
JP4044839B2 (ja) *	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体
JP4102185B2 (ja) *	2000-06-30	2008-06-18	グラクソグループリミテッド	キナゾリンジトシル酸塩化合物
MXPA02012905A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como agentes de dano vascular..
WO2002008213A1 (fr)	2000-07-07	2002-01-31	Angiogene Pharmaceuticals Limited	Derives de colchinol utiles comme inhibiteurs de l'angiogenese
US7253184B2 (en) *	2000-11-02	2007-08-07	Astrazeneca Ab	4-Substituted quinolines as antitumor agents
SE0100569D0 (sv) *	2001-02-20	2001-02-20	Astrazeneca Ab	New compounds
WO2002083622A2 (fr) *	2001-04-10	2002-10-24	Leo Pharma A/S	Nouveaux derives d'aminophenyle cetone
GB0126433D0 (en) *	2001-11-03	2002-01-02	Astrazeneca Ab	Compounds
BR0213842A (pt) *	2001-11-03	2004-08-31	Astrazeneca Ab	Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável
US6756006B1 (en) *	2002-03-05	2004-06-29	Peter Levijoki	Method of forming sculptured designs onto a substrate
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
US6924285B2 (en) *	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7488823B2 (en) *	2003-11-10	2009-02-10	Array Biopharma, Inc.	Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050122199A (ko) *	2003-01-23	2005-12-28	티.케이. 시그널 리미티드	표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도
PE20040945A1 (es) *	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
EP1636195A1 (fr) *	2003-05-27	2006-03-22	Pfizer Products Inc.	Quinazolines et pyrido 3,4-d] pyrimidines utilises comme inhibiteurs de recepteurs tyrosine kinase
WO2005007083A2 (fr) *	2003-06-18	2005-01-27	Smithkline Beecham Corporation	Composes chimiques
NZ545459A (en) *	2003-08-14	2009-12-24	Array Biopharma Inc	Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) *	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
DE10337942A1 (de) *	2003-08-18	2005-03-17	Merck Patent Gmbh	Aminobenzimidazolderivate
SG135193A1 (en) *	2003-08-18	2007-09-28	Pfizer Prod Inc	Dosing schedule for erbb2 anticancer agents
US7399865B2 (en) *	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
GB0321648D0 (en) *	2003-09-16	2003-10-15	Astrazeneca Ab	Quinazoline derivatives
EP1664028A1 (fr) *	2003-09-16	2006-06-07	AstraZeneca AB	Dérivés de quinozaline en tant qu'inhibiteurs de la tyrosine kinase
JP2007510708A (ja) *	2003-11-06	2007-04-26	ファイザー・プロダクツ・インク	癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
KR100735639B1 (ko) *	2004-12-29	2007-07-04	한미약품 주식회사	암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
DE602006009968D1 (de)	2005-11-15	2009-12-03	Array Biopharma Inc	N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten

2006
- 2006-11-15 DE DE602006009968T patent/DE602006009968D1/de active Active
- 2006-11-15 AT AT09157031T patent/ATE507224T1/de active
- 2006-11-15 CA CA2755268A patent/CA2755268C/fr active Active
- 2006-11-15 PT PT09157031T patent/PT2090575E/pt unknown
- 2006-11-15 CA CA2632194A patent/CA2632194C/fr active Active
- 2006-11-15 BR BRPI0618668-8A patent/BRPI0618668B1/pt active IP Right Grant
- 2006-11-15 SI SI200630539T patent/SI1971601T1/sl unknown
- 2006-11-15 SG SG200902466-2A patent/SG152230A1/en unknown
- 2006-11-15 DE DE602006021645T patent/DE602006021645D1/de active Active
- 2006-11-15 CN CN201210320423.2A patent/CN102887891B/zh active Active
- 2006-11-15 PL PL09157031T patent/PL2090575T3/pl unknown
- 2006-11-15 EP EP09157031A patent/EP2090575B1/fr active Active
- 2006-11-15 SI SI200631044T patent/SI2090575T1/sl unknown
- 2006-11-15 DK DK09157031.7T patent/DK2090575T3/da active
- 2006-11-15 JP JP2008541330A patent/JP5134548B2/ja active Active
- 2006-11-15 CN CNA2006800506892A patent/CN101356171A/zh active Pending
- 2006-11-15 PT PT06837728T patent/PT1971601E/pt unknown
- 2006-11-15 RU RU2011122539/04A patent/RU2592703C9/ru active
- 2006-11-15 RU RU2008118417/04A patent/RU2428421C2/ru active
- 2006-11-15 WO PCT/US2006/044431 patent/WO2007059257A2/fr not_active Ceased
- 2006-11-15 ES ES06837728T patent/ES2335535T3/es active Active
- 2006-11-15 EP EP06837728A patent/EP1971601B1/fr active Active
- 2006-11-15 AU AU2006315383A patent/AU2006315383B2/en active Active
- 2006-11-15 KR KR1020087014416A patent/KR101086967B1/ko active Active
- 2006-11-15 DK DK06837728.2T patent/DK1971601T3/da active
- 2006-11-15 ZA ZA200804498A patent/ZA200804498B/xx unknown
- 2006-11-15 BR BR122018075851-1A patent/BR122018075851B1/pt active IP Right Grant
- 2006-11-15 ES ES09157031T patent/ES2364901T3/es active Active
- 2006-11-15 US US12/085,048 patent/US8648087B2/en active Active
- 2006-11-15 AT AT06837728T patent/ATE446294T1/de active
- 2006-11-15 PL PL06837728T patent/PL1971601T3/pl unknown
2008
- 2008-06-10 NO NO20082598A patent/NO342413B1/no unknown
2010
- 2010-01-15 CY CY20101100043T patent/CY1110583T1/el unknown
- 2010-06-04 AU AU2010202330A patent/AU2010202330B2/en active Active
- 2010-09-06 JP JP2010198848A patent/JP5232841B2/ja active Active
2011
- 2011-07-15 CY CY20111100696T patent/CY1112754T1/el unknown
2013
- 2013-09-23 US US14/034,361 patent/US9693989B2/en active Active
2015
- 2015-06-02 IL IL239149A patent/IL239149A/en active IP Right Grant
2016
- 2016-11-15 IL IL248993A patent/IL248993B/en active IP Right Grant
2017
- 2017-05-19 US US15/599,867 patent/US20170252317A1/en not_active Abandoned
2018
- 2018-05-09 US US15/975,323 patent/US10780073B2/en active Active
2020
- 2020-07-27 US US16/940,091 patent/US20210008023A1/en not_active Abandoned
2021
- 2021-07-06 NL NL301113C patent/NL301113I2/nl unknown
- 2021-07-09 CY CY2021019C patent/CY2021019I2/el unknown
- 2021-07-09 FI FIC20210022C patent/FIC20210022I1/fi unknown
- 2021-07-20 LT LTPA2021516C patent/LTC1971601I2/lt unknown
- 2021-07-20 LU LU00217C patent/LUC00217I2/fr unknown
- 2021-07-20 FR FR21C1031C patent/FR21C1031I2/fr active Active
- 2021-07-29 HU HUS2100028C patent/HUS2100028I1/hu unknown
2022
- 2022-09-08 US US17/940,902 patent/US12171739B2/en active Active

Also Published As

Publication number	Publication date
US9693989B2 (en)	2017-07-04
ZA200804498B (en)	2009-07-29
RU2592703C2 (ru)	2016-07-27
BRPI0618668B1 (pt)	2021-09-21
LTC1971601I2 (fr)	2022-10-25
CA2755268C (fr)	2013-12-31
CN101356171A (zh)	2009-01-28
CA2632194A1 (fr)	2007-05-24
AU2006315383B2 (en)	2011-06-02
HK1129678A1 (en)	2009-12-04
CA2632194C (fr)	2012-01-03
PT2090575E (pt)	2011-06-06
HK1119174A1 (en)	2009-02-27
HUS2100028I1 (hu)	2021-08-30
JP5232841B2 (ja)	2013-07-10
KR101086967B1 (ko)	2011-11-29
CN102887891B (zh)	2016-03-09
US20210008023A1 (en)	2021-01-14
KR20080070064A (ko)	2008-07-29
DE602006009968D1 (de)	2009-12-03
DK2090575T3 (da)	2011-05-23
AU2010202330A1 (en)	2010-07-01
LUC00217I2 (fr)	2022-10-07
CY1110583T1 (el)	2015-04-29
RU2008118417A (ru)	2009-12-27
PT1971601E (pt)	2010-01-26
SI2090575T1 (sl)	2011-08-31
RU2428421C2 (ru)	2011-09-10
EP2090575B1 (fr)	2011-04-27
FR21C1031I1 (fr)	2021-08-27
NL301113I2 (nl)	2021-08-03
JP5134548B2 (ja)	2013-01-30
WO2007059257A8 (fr)	2007-07-12
JP2010270154A (ja)	2010-12-02
NO342413B1 (no)	2018-05-22
US8648087B2 (en)	2014-02-11
CY1112754T1 (el)	2016-02-10
IL248993B (en)	2018-11-29
DE602006021645D1 (de)	2011-06-09
PL2090575T3 (pl)	2011-09-30
US20230142839A1 (en)	2023-05-11
US12171739B2 (en)	2024-12-24
BRPI0618668A2 (pt)	2011-09-06
IL248993A0 (en)	2017-01-31
NO20082598L (no)	2008-08-06
WO2007059257A3 (fr)	2007-08-23
DK1971601T3 (da)	2010-02-08
ATE507224T1 (de)	2011-05-15
US20110034689A1 (en)	2011-02-10
US20140023643A1 (en)	2014-01-23
IL239149A (en)	2016-11-30
CY2021019I1 (el)	2021-10-15
EP1971601A2 (fr)	2008-09-24
AU2010202330B2 (en)	2012-07-19
ES2364901T3 (es)	2011-09-16
CA2755268A1 (fr)	2007-05-24
JP2009515988A (ja)	2009-04-16
AU2006315383A1 (en)	2007-05-24
EP2090575A1 (fr)	2009-08-19
LTPA2021516I1 (fr)	2021-08-10
ES2335535T3 (es)	2010-03-29
FIC20210022I1 (fi)	2021-07-09
WO2007059257A2 (fr)	2007-05-24
RU2592703C9 (ru)	2016-10-20
SI1971601T1 (sl)	2010-03-31
NL301113I1 (nl)	2021-07-01
CN102887891A (zh)	2013-01-23
BR122018075851B1 (pt)	2022-01-11
CY2021019I2 (el)	2021-12-31
US10780073B2 (en)	2020-09-22
EP1971601B1 (fr)	2009-10-21
ATE446294T1 (de)	2009-11-15
IL239149A0 (en)	2015-07-30
US20170252317A1 (en)	2017-09-07
RU2011122539A (ru)	2012-12-10
SG152230A1 (en)	2009-05-29
PL1971601T3 (pl)	2010-03-31
US20180271824A1 (en)	2018-09-27

Publication	Publication Date	Title
FR21C1031I2 (fr)	2022-07-15	Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives
CY1112402T1 (el)	2015-12-09	Ενισχυτες υποδοχεων γλουταμικου
CY1107005T1 (el)	2012-09-26	Ετεροπολυκυκλικες ενωσεις και οι χρησεις τους ως ανταγωνιστες των μεταβοτροπικων υποδοχέων του γλουταμικου
UY29927A1 (es)	2007-06-29	Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
SE0203713D0 (sv)	2002-12-13	Novel compounds
BRPI0508051A (pt)	2007-07-17	derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA200600071A1 (ru)	2006-08-25	Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
MX2007011847A (es)	2008-03-11	Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
DE60222286D1 (de)	2007-10-18	Verfahren zur erhöhung des testosteronspiegels
EA200600416A1 (ru)	2006-08-25	Производные циклопропила в качестве антагонистов рецептора nk3
UA97235C2 (ru)	2012-01-25	Производные хиназолина и конденсированного пиримидина в качестве ингибитора erbb
SE0303488D0 (sv)	2003-12-19	New use 1X
SE0303419D0 (sv)	2003-12-17	New use 11